Research programme: rheumatoid arthritis therapy - Green Cross
Latest Information Update: 01 Mar 2011
At a glance
- Originator Green Cross
- Mechanism of Action T lymphocyte inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 09 Mar 2006 Preclinical trials in Rheumatoid arthritis in South Korea (unspecified route)